Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 325

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 325
---
, 2021, the Company consummated the IPO of 15,500,000units (“Units”) (with respect to the Class A common stock included in the Units being offered (the “Public Shares”)) at $ 10.00per Unit generating gross proceeds of $ 155,000,000, which is discussed in Note 3. The Company has selected December 31 as its fiscal year end. Simultaneously with the closing of the IPO, the Company consummated the sale of 845,000units (“Private Placement Units”) (with respect to the Class A common stock included in the Private Placement Units offered, the “Private Placement Shares”) at a price of $ 10.00per Private Placement Unit in a private placement to the Company’s sponsor, Phoenix Biotech Sponsor, LLC (the “Sponsor”), Cantor Fitzgerald & Co. (“Cantor”) and Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (“CCM”), generating gross proceeds of $ 8,450,000, which is described in Note 4. Simultaneously with the closing of the IPO, the Company consummated the sale of 2,000,000additional Units upon receiving notice of the underwriter’s election to partially exercise its overallotment option (“Overallotment Units”), generating additional gross proceeds of $ 20,000,000and incurring additional offering costs of $ 1,400,000in underwriting fees, all of which are deferred until the completion of the Company’s initial business combination. Simultaneously with the exercise of the overallotment, the Company consummated the Private Placement of an additional 40,000Private Placement Units to the Sponsor and CCM, generating gross proceeds of $ 400,000. Offering costs for the IPO and exercise of the overallotment option amounted to $ 12,729,318, consisting of $ 2,635,000of underwriting fees, $ 9,150,000of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $ 944,318of other costs. As described in Note 6, the $ 9,150,000of deferred underwriting fees payable is contingent upon the consummation of a business combination by January 8, 2024, subject to the terms of the underwriting agreement. Following the closing of the IPO, $ 178,500,000($ 10.20per Unit)